Malignant transformation of ovarian endometriosis. Nature, treatment and report of two cases.
D000230:Adenocarcinoma / Q000150:complications / Q000473:pathology* / Q000628:therapy; D002280:Basal Cell Carcinoma / Q000150:complications; D002561:Cerebrovascular Disorders / Q000209:etiology; D003036:Cobalt Isotopes; D004487:Edema / Q000209:etiology / Q000473:pathology; D004715:Endometriosis / Q000150:complications / Q000473:pathology* / Q000628:therapy; D004848:Epithelium; D004967:Estrogens / Q000378:metabolism*; D005153:Facial Neoplasms / Q000150:complications; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use; D008198:Lymph Nodes / Q000473:pathology; D008525:Medroxyprogesterone / Q000627:therapeutic use; D008875:Middle Aged; D009130:Muscle, Smooth / Q000473:pathology; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000150:complications / Q000473:pathology* / Q000628:therapy; D010053:Ovary / Q000378:metabolism; D010759:Phosphorus Isotopes; D012878:Skin Neoplasms / Q000150:complications
D003036:Cobalt Isotopes; D004967:Estrogens; D006908:Hydroxyprogesterones; D010759:Phosphorus Isotopes; D008525:Medroxyprogesterone